Estimated reading time: 2 minutes
Biotech company Orbis Health Solutions is making significant strides in the development of a groundbreaking cancer treatment. This treatment is aimed at minimizing debilitating side effects. Traditional cancer therapies, such as chemotherapy, often result in adverse effects that can be as distressing as the disease itself. Many traditional cancer treatments work by killing off cancer cells but also kill off non-cancerous cells throughout the body. This can cause a number of serious side effects including hair loss, nausea, and vomiting.
Orbis's pioneering approach involves the creation of a personalized cancer vaccine, known as the tumor lysate particle only (TLPO) vaccine. Unlike conventional treatments, the TLPO vaccine harnesses the power of the patient's immune system. By treating the cancer like a virus, the immune system can identify cancer cells and fight the cancer itself. The new treatment targets and eliminates cancer cells, offering the potential for a more effective and less disruptive treatment.
Phase Trials
Phase 2 clinical trials of the TLPO cancer vaccine, conducted on patients with advanced melanoma, have yielded promising outcomes. Nearly 95% of participants were still alive three years after commencing treatment, with 64% remaining disease-free. These encouraging results have paved the way for the approval of a Phase 3 clinical trial by the FDA. This signals a significant step toward validating the vaccine's efficacy on a larger scale.
The upcoming Phase 3 clinical trial, a $100 million endeavor, is set to enroll 500 participants, commencing later this year. The goal is to further substantiate the vaccine's potential as a transformative force in the field of cancer treatment.
Potential Obstacles
Despite the positive outlook, financial barriers pose challenges for smaller companies like Orbis Health Solutions. To overcome these obstacles and extend the reach of this groundbreaking treatment, they have initiated a basket trial. This FDA-approved clinical trial allows testing of the TLPO vaccine on individuals with various solid tumors. The hope is this will showcase early success and minimal side effects.
The success of the basket trial is anticipated to attract attention from larger pharmaceutical companies, fostering potential partnerships and securing funding for more extensive clinical trials. While success in Phase 3 trials and FDA approval are crucial milestones, the TLPO cancer vaccine holds promise as a transformative and minimally invasive solution in the quest for effective cancer treatment.
Did you find this article interesting? PatientsLikeMe is committed to bringing the latest in health news to our members. Creating an account is free! Join today.